|
|
|
|
IQ 532® Laser System – Dual port green laser for comprehensive ophthalmology.
NEW- MicroPulse® Laser Therapy for repeatable, tissue-sparing* glaucoma and retinal therapies.
PRODUCT HIGHLIGHTS
- High power for greater range of therapy alternatives
- Dual port for efficient setup of alternate delivery devices
- Repeatable laser sessions for retinal diseases with optional MicroPulse module
|
Schedule a hands-on demo Schedule a no-obligation demo to see for yourself how MicroPulse Technology and IRIDEX’s Family of Products can take YOUR practice to the next level.
|
The Advantages of Innovation - High power for greater range of therapy alternatives
- High speed pulse durations for faster procedural time
- DualSense provides quick and simple selection of multiple delivery devices for RFID and SMA
Intelligent and intuitive design - Dual Port for efficient setup of alternate delivery devices
- Intuitive graphic touch screen interface for ease of use
- Programmable memory presets for multiple users
Optional Module for MicroPulse Laser Therapy, Fovea-Friendly* - Repeatable laser sessions for retinal diseases
- Repeatable glaucoma therapy with MicroPulse laser trabeculoplasty (MLT)
Wavelength |
532 nm Green |
Weight |
19.2 lb (9.0 kg) |
Dimensions |
8.5" H x 12" W x 14" D
(21 cm x 30 cm x 35 cm)
|
Connector Type
|
RFID | Resistor |
Electrical |
100-240 VAC, 50/60 Hz
|
Cooling |
Whisper fan
|
Exposure Duration |
CW-Pulse: 10-3000 ms
|
Exposure Interval |
CW-Pulse: 10-3000 ms
|
MicroPulse Duration |
MicroPulse: 0.05-1.00 ms
|
MicroPulse Interval |
MicroPulse: 1.00-10.00 ms
|
Aiming Laser |
Diode laser, 635 nm nominal
|
Delivery Device Power Output |
Portable SLA: 0-2000 mW
LIO: 0-2000 mW
EndoProbe: 0-2000 mW
|
| | IQ 532 Laser Product Video |
| | CombiningTissue-sparingMicroPulseTM LaserTherapyand Anti-VEGF Medication Produces Unprecedented Results in Radiation Retinopathy MicroPulse is a laser energy delivery modality that enables fine control of the thermal effects of photoco- agulation... Download Now | | | MicroPulse™ Case Report - Diabetic Macular Edema IRIDEX has set the standard for probe technology, meeting surgical needs for small-gauge probes that consistently and accurately deliver laser treatment at a safe distance from the retina, without sacrificing illumination. Download Now | | | 532 nm Subthreshold MicroPulse Effectively Reduces Diabetic Macular Edema after Failed Conventional Laser Treatment IRIDEX has set the standard for probe technology, meeting surgical needs for small-gauge probes that consistently and accurately deliver laser treatment at a safe distance from the retina, without sacrificing illumination. Download Now |
Optional Accessories Full-Featured Remote Control - Compact design for easy placement or use in sterile field
- View displays and adjust parameters from two vantage points for increased convenience and efficiency
Wireless Footswitch - No cord, no clutter, no limitations
- Allows precise physician control over power settings
- Available with power-adjust to control laser actuation and power settings
Munir Escaf, MD Retina Specialist Clinica Carriazo Barranquilla Atlantico, Columbia | | Jonathan Feistman, MD Retina Specialist NYC Retina New York City, NY | | Brian Horsman, MD Director, Retina Group Barnet Dulaney Perkins Eye Center Phoenix, AZ USA | | Brandon Johnson, MD NYC Retina New York, NY USA | | Ahad Mahootchi, MD Medical Director The Eye Clinic of Florida Zephyrhills, FL | | Walid Mangal, DO Florida Vision Institute Stuart, FL USA | | "By incorporating MicroPulse, my injection burden decreases by one-third at a minimum, which is a conservative estimate. The versatility of MicroPulse to treat retinal disorders and glaucoma allows me to provide my patients with a treatment that’s clinically effective, cost effective, and time effective.""MLT is both safe and durable. This therapy can be considered a first-line treatment for glaucoma patients, as well as patients who haven’t seen significant effects from medications." Jason Friedrichs, MD, MS Friedrichs Eye Sycamore, IL USA | "Compared to other lasers, the IQ 532 Laser with the MicroPulse module offers greater versatility because it can also be used for a range of other conditions including diabetic macular edema, proliferative diabetic retinopathy, and retinal tears. I'm comfortable offering MLT to glaucoma patients as a first-line option because of its potential to reduce intraocular pressure without causing tissue damage." David Gossage, DO, FAOCO, FAAO Gossage Eye Institute Hillsdale, MI USA | "The MicroPulse P3 Device has become an essential part of my armamentarium for use in glaucoma surgical procedures. It provides a very safe and efficacious solution for IOP control. I have used MicroPulse P3 for some of my most complicated cases but also I feel comfortable enough using it for patients with earlier disease in which we want to avoid a filtering bleb or the placement of hardware in the eye." Robert Noecker, MD, MBA Ophthalmic Consultants of Connecticut Fairfield, CT USA | "...treatment is less difficult and often takes less time than 532 nm." Dr. John T. Harriott Winston-Salem, NC | "The IQ532 Tx Cell Laser System is an invaluable adjunct in my armamentarium for a growing multitude of retinal and choroidal pathologies. In my hands, micropulse laser technology has achieved significant anatomic and functional gains as primary and combination therapy. The TxCell pattern delivery dramatically increases laser application efficiency, as well as patient comfort." Caesar Luo, MD Bay Area Retina Associates Oakland, CA USA | "I have found the MicroPulse P3 Device to be a non-incisional, easy, and safe way to reduce pressure anytime my patients need it, and it is predictable and highly efficacious." Melissa Toyos, MD Toyos Clinic Nashville, TN USA | "MLT is both safe and durable. This therapy can be considered a first-line treatment for glaucoma patients, as well as patients who haven’t seen significant effects from medications." Ike Ahmed, MD, FRCSC Prism Eye Institute Toronto, Ontario, Canada | "I have been impressed that the MicroPulse P3 therapy with the Cyclo G6 Glaucoma Laser can deliver pressure lowering in a broad range of glaucomas, including mild and moderate patients who I want to free from the adverse effects of drops." Rolando Toyos, MD Toyos Clinic Nashville, TN USA | "The visualization of the ciliary body and the surrounding area is impressive. It has really helped me to deliver a patient-specific, targeted CPC treatment with an easy-to-use probe." Steven Vold, MD Vold Vision Fayetteville, AR USA | "You can really consider TSCPC in almost all glaucoma situation, even malignant glaucoma. It is not just relegated to end-stage treatment anymore." Dr. Jeffrey Kammer Vanderbilt Eye Institute Nashville, TN | "TSCPC is a surgery that can be done before or after any other surgery. It is very versatile from that standpoint. " Nathan Radcliffe, MD New York Eye Surgery Center Bronx, NY USA | "Recovery with TSCPC is much more rapid and the postoperative care much less involved than with someone who has had an incisional glaucoma case in a surgical center." Steven Vold, MD Vold Vision Fayetteville, AR USA | Lawrence Morse, MD, PhD UC Davis Davis, CA USA | | Kishiko Ohkoshi, MD Professor, Director, Chief Vitreoretinal Surgeon St. Luke’s International University Tokyo, Japan | | Julia Schulman, MD NYC Retina New York, NY USA | | Stela Vujosevic, MD Professor, Medial Retina Specialist University Hospital Maggiore della Carita Novara, Italy | | Glenn Yiu, MD, PhD UC Davis Davis, CA USA | | Marco Zarbin, MD, PhD, FACS Rutgers New Jersey Medical School Newark, NJ USA | | MLT Focused "I achieved such good results with MLT that I decided to try MicroPulse for treating retinal diseases. I now use it daily to treat many retinal disorders, and MicroPulse allows me to treat patients who I could not have otherwise." Brandon Philips, MD Carolina Vision Center Fayetteville, NC USA | "MLT is versatile in variety of ways: for patients just starting therapy, replacing an eye drop, as an adjunct to an eye drop or to keep them away from incisional surgery." Nathan Radcliffe, MD New York Eye Surgery Center Bronx, NY USA |
September 11, 2019: MicroPulse® Transscleral Laser Therapy Will be Discussed in Various Presentations and Educational Events at ESCRS 2019 in Paris, France June 3, 2019: Laser treatment for DME: Still a place at the table May 1, 2019: Study shows MicroPulse Laser controls IOP after Karatoplasty April 29, 2019: MicroPulse Laser featured in several Glaucoma and Retina research presentations at Ophthalmic Industry Conferences April 10, 2019: Meet MicroPulse TSCPC Experts at ASCRS in San Diego on May 4-6, 2019 April 8, 2019: ASCRS Breakfast: MicroPulse TSCPC as a Treatment for Failed MIGS Procedures April 1, 2019: The Role of Laser for Retinal Vascular Disease in the Anti-VEGF Era April 1, 2019: MicroPulse featured in multiple abstracts, posters, and presentations at WGC March 1, 2019: How does wavelength factor into choosing a laser? by Caesar Luo, MD January 14, 2019: Subthreshold Laser Treatment for Macular Edema by Matteo Forlini, MD June 25, 2018: IRIDEX Announces Multiple Studies of MicroPulse® Laser Therapy Published at World Ophthalmology Congress May 17, 2018: IRIDEX MicroPulse Technology Featured In Many Scientific Presentations at the European Glaucoma Society Meeting May 02, 2018: IRIDEX Announces Dramatic Increase In MicroPulse Visibility at the 2018 ARVO Meeting September 06, 2017: IRIDEX Explored on Innovations Breakthrough Series
|
|
|
*Bhagat N, Zarbin M, Mansour S, Chong V, and Cardillo JA. Fovea-friendly MicroPulse Laser. Supplement to Retina Today, May/June 2012
|
|
|